Physician profile
Jorge Juncos
NPI 1184801383
$11,238.05
in general payments reported to CMS, 2019-2025
22 companies · $766 in 2025
The $766 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,144 · 2021: $516 · 2022: $1,430 · 2023: $802 · 2024: $580 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,147.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $7,216.41 | 2019-2023 | Austedo Xr |
| Acadia Pharmaceuticals INC | $944.66 | 2021-2025 | Nuplazid |
| Emd Serono, INC. | $854.20 | 2022-2025 | Mavenclad |
| Abbvie INC. | $466.23 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $409.00 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $192.90 | 2022 | |
| Supernus Pharmaceuticals, INC. | $166.99 | 2023-2024 | Qelbree, Qelbree |
| Kyowa Kirin, INC. | $147.59 | 2019-2022 | |
| Mdd US Operations, LLC | $137.66 | 2024 | Gocovri |
| W. L. Gore & Associates, INC. | $135.01 | 2021-2022 | |
| Abbott Laboratories | $128.26 | 2023 | Infinity |
| Amneal Pharmaceuticals LLC | $124.11 | 2025 | Crexont |
| Livanova USA, INC. | $112.00 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Biogen, INC. | $71.72 | 2022 | |
| Lundbeck LLC | $26.38 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $20.04 | 2022 | |
| Merz Pharmaceuticals, LLC | $18.10 | 2022 | |
| Harmony Biosciences LLC | $17.70 | 2022 | |
| Argenx US, INC. | $17.64 | 2022 | |
| Lilly USA, LLC | $17.21 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $14.24 | 2025 | Rexulti |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Juncos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.